Johnson & Johnson's medical devices segment, MedTech, reported strong second-quarter sales of $8.54 billion, up 7.3% year-over-year, exceeding the Zacks Consensus Estimate of $8.25 billion. Sales growth was driven by strong performance in cardiovascular, surgery, and vision markets, with operational growth of 6.1% and a positive currency impact of 1.2%. Excluding acquisitions, divestitures, and currency, adjusted operational sales rose 4.1%. U.S. sales increased 8.0% and international sales rose 4.1% on an operational basis. Growth was fueled by newly acquired cardiovascular businesses Abiomed and Shockwave, as well as improvements in surgical vision and wound closure. However, sales in China are being negatively impacted by the government's volume-based procurement (VBP) program. J&J expects continued improvement in the second half of 2025 as new products gain momentum, though VBP-related headwinds are expected to persist. The company outperformed the industry in stock performance, rising 22.2% year-to-date versus a 6.7% industry decline. J&J trades at a forward P/E of 15.57, above the industry average of 13.71 but below its five-year mean of 15.66. The Zacks Consensus Estimate for 2025 earnings has increased from $10.64 to $10.86 per share, with a recent 30-day update to $11.36 per share. J&J holds a Zacks Rank #2 (Buy).

Johnson & Johnson's MedTech segment reported strong second-quarter sales of $8.54 billion, up 7.3% year-over-year, exceeding the Zacks Consensus Estimate of $8.25 billion. The growth was driven by operational improvements of 6.1% and positive currency impacts of 1.2%, with adjusted operational sales rising 4.1%. Key growth areas included Cardiovascular, Surgery, and Vision, with U.S. sales increasing 8.0% and international sales rising 4.1% on an operational basis. Growth was fueled by newly acquired businesses Abiomed and Shockwave, as well as improvements in Surgical Vision and wound closure. However, sales in China are negatively impacted by the government's volume-based procurement (VBP) program. The company expects continued improvement in the second half of 2025 as new products gain momentum, though VBP-related headwinds are expected to persist. J&J's stock has outperformed the industry year-to-date, rising 22.2% versus a 6.7% industry decline, though it trades at a higher forward P/E of 15.57 compared to the industry's 13.71. The Zacks Consensus Estimate for 2025 earnings has increased to $10.86 per share, up from $10.64.

DelveInsight's 2030 market report on cardiac assist devices provides a comprehensive analysis of the global market, estimating its value at USD 2.89 billion in 2023, with a projected compound annual growth rate (CAGR) of 13.70% from 2024 to 2030, reaching USD 6.23 billion by 2030. North America is projected to hold the largest market share in 2023, driven by high prevalence of cardiovascular diseases, limited heart donor availability, and increasing demand for advanced cardiac assist technologies. The report highlights key market drivers including rising prevalence of heart failure and coronary artery disease, growing awareness and screening programs, and a surge in product launches and regulatory approvals. The market is segmented by product type, therapy, end-user, and geography. Globally, approximately 620 million people live with heart and circulatory diseases, with significant regional variations in prevalence, particularly in Europe and Asia and Australia. The report identifies leading companies such as Abbott Laboratories, Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc, CARMAT, CorWave SA, Medtronic PLC, Terumo Heart, Inc., NovaPump GmbH, Getinge AB, Balton Ltd., Meril Life Sciences Pvt. Ltd., Thoratec Corporation, CardiacAssist, Inc., Berlin Heart GmbH, BrioHealth Solutions, Inc., BiVACOR, Inc., Magenta Medical, Abiomed, and SynCardia as key players in the market.

The Artificial Organ Market is projected to grow from USD 21.51 Bn in 2025 to USD 38.32 Bn by 2032, with a compound annual growth rate (CAGR) of 8.6%. The report analyzes market trends, competitive landscape, technological advancements, and regional segmentation, highlighting key players like Abbott Laboratories, Medtronic, and Boston Scientific. It provides insights into product types, applications, and geographic markets, along with strategic recommendations for industry stakeholders.

Johnson & Johnson reported strong second-quarter 2025 results, with sales and earnings exceeding expectations. Despite losing exclusivity for its blockbuster drug Stelara, the company outperformed in key segments like Innovative Medicines and MedTech. J&J raised its annual sales and EPS guidance, driven by currency tailwinds and reduced tariff costs. The stock rose 6% following the earnings report, but long-term investors should focus on the company’s diversified business model, strong R&D pipeline, and growth prospects in oncology and MedTech. Challenges include Stelara biosimilars, talc lawsuits, and potential pharmaceutical tariffs.